In an in vivo experiment using engineered mice harboring ARID1A loss and PIK3CA mutations, treatment with the PIK3 inhibitor buparlisib led to a dose-dependent reduction in AKT levels and tumor viability, highlighting the therapeutic potential of buparlisib in OCCC with these co-mutations [32]. This evidence concerns the gene AKT1 and neoplasm.